How people choose in this industry
A formulator's sourcing team starts with a molecule and a grade. It looks for suppliers in a database, at pharma ingredient trade events, and by asking trade contacts. The short list then gets a request for a sample, a certificate of analysis, a drug master file reference where relevant, an impurity profile and a plant audit. A supplier whose first reply carries all of it has an edge over a larger name who needs three emails.
The technical team in R&D or quality assurance holds the real veto. They compare the impurity profile with the one they already use, check the particle size and polymorph if that matters, and decide whether a second source is worth the work. Purchase then negotiates price, but only for suppliers who passed the technical test.
For regulated-market buyers, the plant's inspection history and the right filings decide whether the conversation starts at all. For domestic buyers, supply reliability and a steady quality across batches count most.
The decision before implementation
Resolve an outstanding delivery issue before asking for advocacy or another purchase. Respect contact preferences.
Existing industry priorities to review
- Second-source qualification at formulators
- Contract manufacturers who buy APIs for others
- Overseas importers and distributors
- Repeat orders from trialled buyers
- Custom synthesis enquiries
These describe the industry's wider priorities. The written scope identifies which this service will address.